Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment and antiretroviral therapy in an area of low tuberculosis transmission

Clinical Infectious Diseases

Volumn 44, Issue 1, 2007, Pages 94-102

  Elzi, Luigia ^a   Schlegel, Matthias ^b   Weber, Rainer ^c   Hirschel, Bernard ^d   Cavassini, Matthias ^e   Schmid, Patrick ^g,k   Bernasconi, Enos ^h   Rickenbach, Martin ^f,i   Furrer, Hansjakob ^b,i   Battegay, M ^e   Bernasconi, E ^e   Boni J ^e   Bucher, H ^e   Burgisser Ph ^e   Cattacin, S ^e   Dubs, R ^e   Egger, M ^e   Elzi, L ^e   Erb, P ^e   Fischer, M ^e   Flepp, M ^e   Fontana, A ^e   Francioli, P ^e   Gorgievski, M ⁱ   Gunthard H ⁱ   Hosli I ⁱ   Kahlert, Ch ⁱ   Kaiser, L ⁱ   Karrer, U ⁱ   Keiser, O ⁱ   Kind, C ⁱ   Klimkait, Th ⁱ   Ledergerber, B ⁱ   Martinez, B ⁱ   Muller N ⁱ   Nadal, D ⁱ   Opravil, M ⁱ   Paccaud, F ⁱ   Pantaleo, G ⁱ   Perrin, L ⁱ   Piffaretti, J C ⁱ   Rudin, C ^j   Schultze, D ^k   Schupbach J ^k   Speck, R ^k   Taffe P ^k   Tarr, P ^k   Telenti, A ^k   Trkola, A ^k   Vernazza, P ^k   Yerly, S ^k   more..

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f Swiss HIV Cohort Study Data Center   (Switzerland)

^g CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^h REGIONAL HOSPITAL OF LUGANO   (Switzerland)

ⁱ Clinical and Laboratory Committee   (Switzerland)

^j Data Center

^k Clinical and Laboratory Committee ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; ISONIAZID; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; VIRUS RNA;

ADULT; AFRICA; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE MARKER; DISEASE TRANSMISSION; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RISK REDUCTION; SCREENING; SWITZERLAND; TUBERCULIN TEST; TUBERCULOSIS;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TUBERCULIN TEST; TUBERCULOSIS;

EID: 33845712173     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/510080     Document Type: Article

References (36)

1. Corbett EL, Steketee RW, ter Kuile FO, Latif AS, Kamali A, Hayes RJ. HIV-1/AIDS and the control of other infectious diseases in Africa. Lancet 2002; 359:2177-87.
2. Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1999; 340:367-73.
3. Goletti D, Weissman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis on HIV replication: role of immune activation. J Immunol 1996; 157:1271-8.
4. Sudre P, Hirschel B, Toscani L, Ledergerber B, Rieder HL. Risk factors for tuberculosis among HIV-infected patients in Switzerland. Swiss HIV Cohort Study. Eur Respir J 1996; 9:279-83.
5. Staehelin C, Rickenbach M, Low N, et al. Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival. AIDS 2003; 17:2237-44.
6. Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 2002;51(RR-8):1-52.
7. Sudre P, Rieder H, Bassetti S, Hirschel BJ, Ledergerber B, Malvy D. HIV infection, tuberculosis and tuberculin test in Switzerland. The Swiss HIV Cohort Study [in German]. Schweiz Med Wochenschr 1996; 126:2007-12.
8. Huebner RE, Schein MF, Bass JB Jr. The tuberculin skin test. Clin Infect Dis 1993; 17:968-75.
9. Jasmer RM, Nahid P, Hopewell PC. Clinical practice: latent tuberculosis infection. N Engl J Med 2002; 347:1860-6.
10. Iseman M. A 52-year-old man with a positive PPD. JAMA 2001; 286: 2015-22.
11. Bailey WC, Gerald LB, Kimerling ME, et al. Predictive model to identify positive tuberculosis skin test results during contact investigations. JAMA 2002; 287:996-1002.
12. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993; 342:268-72.
13. Bucher HC, Griffith LE, Guyatt GH, et al. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 1999; 13:501-7.
14. Mwinga A, Hosp M, Godfrey-Faussett P, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998; 12:2447-57.
15. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997; 337:801-8.
16. Markowitz N, Hansen NI, Wilcosky TC, et al. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Pulmonary Complications of HIV Infection Study Group. Ann Intern Med 1993; 119:185-93.
17. Sudre P, Rieder H, Bassetti S, Hirschel BJ, Ledergerber B, Malvy D. HIV infection, tuberculosis and tuberculin test in Switzerland. The Swiss HIV Cohort Study [in German]. Schweiz Med Wochenschr 1996; 126:2007-12.
18. Sudre P, Rickenbach M, Taffé P, et al. Clinical epidemiology and research on HIV infection in Switzerland: the Swiss HIV Cohort Study 1988-2000. Schweiz Med Wochenschr 2000; 130:1493-500.
19. Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000; 49(RR-6):1-51.
20. Allen S, Batungwanayo J, Kerlikowske K, et al. Two-year incidence of tuberculosis in cohorts of HIV-infected and uninfected urban Rwandan women. Am Rev Respir Dis 1992; 146:1439-44.
21. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320:545-50.
22. Wilkinson D, Squire SB, Garner P. Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo controlled trials. BMJ 1998; 317:625-9.
23. Tissot F, Zanetti G, Francioli P, Zellweger JP, Zysset F. Influence of bacille Calmette-Guerin vaccination on size of tuberculin skin test reaction: to what size? Clin Infect Dis 2005; 40:211-7.
24. Girardi E, Palmieri F, Zaccarelli M, et al. High incidence of tuberculin skin test conversion among HIV-infected individuals who have a favourable immunological response to highly active antiretroviral therapy. AIDS 2002; 16:1976-9.
25. Lawn SD, Bekker LG, Wood R. How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS 2005; 19:1113-24.
26. Wendland T, Furrer H, Vernazza P, et al. HAART in HIV-infected patients: restoration of antigen-specific CD4 T-cell responses in vitro is correlated to CD4-memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viremia. AIDS 1999; 13:1857-62.
27. Girardi E, Sabin CA, d'Arminio MA, et al. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis 2005; 41:1772-82.
28. Small PM, Hopewell PC, Singh SP, et al. The epidemiology of tuberculosis in San Francisco: a population-based study using conventional and molecular methods. N Engl J Med 1994; 330:1703-9.
29. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001; 358:1687-93.
30. Ferrara G, Losi M, D'Amico R, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006; 367:1328-34.
31. Pai M, Riley LW, Colford JM Jr. Interferon-γ assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004; 4: 761-76.
32. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005; 54(RR-15):49-55.
33. Antonucci G, Girardi E, Raviglione MC, Ippolito G. Risk factors for tuberculosis in HIV-infected persons: a prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA 1995; 274:143-8.
34. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359:2059-64.
35. Williams BG, Dye C. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science 2003; 301:1535-7.
36. Corbett EL, Marston B, Churchyard GJ, De Cock KM. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 2006; 367:926-37.